Personal Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Personal Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$218K	Sell	756 -102	-12%	-$31.1K	﹤0.01%	450
2022 Q3	$248K	Sell	858 -50	-6%	-$14.4K	﹤0.01%	398
2022 Q2	$256K	Buy	908 +77	+9%	+$20.6K	﹤0.01%	379
2022 Q1	$217K	Sell	831 -312	-27%	-$74K	﹤0.01%	467
2021 Q4	$251K	Buy	1,143 +3	+0.3%	+$583	﹤0.01%	473
2021 Q3	$207K	Buy	+1,140	New	+$223K	﹤0.01%	478

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Personal Capital Advisors's VRTX Position: Q4 2022 in Review

Personal Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 12% in Q4 2022, selling an estimated $31.1K and leaving 756 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #450.

Personal Capital Advisors first reported a position in VRTX in Q3 2021 and has held it in 6 quarters since. The position peaked at $256K in Q2 2022. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Personal Capital Advisors held 756 shares of Vertex Pharmaceuticals worth $218K as of Q4 2022.
Personal Capital Advisors sold 102 Vertex Pharmaceuticals shares in Q4 2022, an estimated $31.1K.
Vertex Pharmaceuticals made up ﹤0.01% of Personal Capital Advisors's portfolio in Q4 2022, its #450 holding.
Personal Capital Advisors first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 6 quarters since.
Personal Capital Advisors's Vertex Pharmaceuticals position peaked at $256K in Q2 2022.
1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Personal Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.